Communiqués Simcere Pharmaceutical Group Limited

Actions

2096

HK0000658531

Produits pharmaceutiques

Temps Différé Hong Kong S.E. 05:58:33 06/10/2026			Varia. 5j.	Varia. 1 janv.
11,59 ^HKD	+1,58 %		+1,93 %	-3,17 %

02/10	Les grands laboratoires pharmaceutiques se tournent vers la Chine pour conclure des accords de licence	RE
30/09	Les grands laboratoires pharmaceutiques se tournent vers la Chine pour leurs accords de licence	RE

Communiqués

12/06	Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis	PR
16/10/25	NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States	AQ
19/06/25	Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma	PR
13/01/25	Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma	PR
13/01/25	AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma	PR
03/09/24	Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor	AQ
03/09/24	TargetRx Signs Collaboration Agreement with Simcere Zaiming	AQ
26/06/24	Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA	PR
21/11/23	Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China	AQ
20/12/22	PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT	PR
29/09/22	Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc	PR
05/09/22	Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue	PR
19/04/22	Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day	PR
07/04/22	SIMCERE PHARMA (HK.2096) to host 2022 R&D Day	PR
23/02/22	Simcere Pharma (2096.HK) Announces a Positive Profit Alert	PR
28/04/21	Simcere Pharmaceutical : FURTHER ANNOUNCEMENT PROFIT FORECAST IN RELATION TO DISPOSAL OF SUBSIDIARIES	PU
16/04/21	Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL ON CLINICAL TRIAL APPLICATION FOR THE ADDITION OF NEW INDICATIONS OF TRILACICLIB FOR INJECTION	PU
15/04/21	Simcere Pharmaceutical : CHANGE IN USE OF PROCEEDS	PU
14/04/21	Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE CLINICAL TRIAL APPROVAL FOR SIM-307 ISSUED BY THE CENTER FOR DRUG EVALUATION OF NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC	PU
31/03/21	Simcere Pharmaceutical : RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER	PU
25/03/21	Simcere Pharmaceutical : Revised Terms of Reference of the Strategy Committee	PU
21/03/21	Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL OF PHASE III CLINICAL TRIAL APPLICATION FOR ADDITION OF NEW INDICATION FOR ENDOSTAR BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA	PU